NCT02230553 2025-07-08
M14LTK
The Netherlands Cancer Institute
Phase 1/2 Completed
Clinical Trials
12 trialsNCT00455039 2023-08-14
INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients
University of New Mexico
Phase 1/2 Withdrawn
NCT00952692 2021-12-20
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
Duke University
Phase 1/2 Completed
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT01783756 2019-11-12
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT00912275 2019-05-06
Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer
National Taiwan University Hospital
Phase 1/2 Completed
NCT00953576 2018-09-04
KHLAD
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01589861 2017-03-28
PIKHER2
Institut Paoli-Calmettes
Phase 1/2 Suspended
NCT01172223 2016-11-02
LAPADO
Sana-Klinikum Lichtenberg
Phase 1/2 Completed
NCT01658358 2013-02-27
ErbB2 Positive Metastatic Breast Cancer
China Medical University Hospital
Phase 1/2 Terminated
NCT01044485 2012-09-25
LapDoc
Centre Georges Francois Leclerc
Phase 1/2 Completed
NCT00316407 2011-02-18
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
Swedish Medical Center
Phase 1/2 Completed